NCT07525141

A Study of JNJ-1761981 in Participants With Solid Tumors

Phase 1 Study of Intratumoral Administration of JNJ-1761981 ER, an Extended Release Chemotherapy, in Participants With Solid Tumors

• Status: Not Yet Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 66 (estimated)
• Sponsor: Johnson & Johnson Enterprise Innovation Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of Part 1 of this study is to determine a safe, tolerable, and feasible recommended total dose of intratumorally administered JNJ-1761981. The purpose of Part 2 of this study is to identify the optimal volumetric dose of JNJ-1761981 for the treatment of tumor lesions.

Conditions

• Neoplasms

Interventions

Type	Name	Description
DRUG	JNJ-1761981	JNJ-1761981 will be administered intratumorally.
DRUG	Cetrelimab	Cetrelimab will be administered intravenously.

Timeline

• Start date: 2026-04-20
• Primary completion: 2028-01-12
• Completion: 2029-01-31
• First posted: 2026-04-13
• Last updated: 2026-04-13

Regulatory

• FDA-regulated drug study